Cargando…
Syndecan-1 (CD138), Carcinomas and EMT
Cell surface proteoglycans are known to be important regulators of many aspects of cell behavior. The principal family of transmembrane proteoglycans is the syndecans, of which there are four in mammals. Syndecan-1 is mostly restricted to epithelia, and bears heparan sulfate chains that are capable...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072910/ https://www.ncbi.nlm.nih.gov/pubmed/33921767 http://dx.doi.org/10.3390/ijms22084227 |
_version_ | 1783684014045921280 |
---|---|
author | Couchman, John R. |
author_facet | Couchman, John R. |
author_sort | Couchman, John R. |
collection | PubMed |
description | Cell surface proteoglycans are known to be important regulators of many aspects of cell behavior. The principal family of transmembrane proteoglycans is the syndecans, of which there are four in mammals. Syndecan-1 is mostly restricted to epithelia, and bears heparan sulfate chains that are capable of interacting with a large array of polypeptides, including extracellular matrix components and potent mediators of proliferation, adhesion and migration. For this reason, it has been studied extensively with respect to carcinomas and tumor progression. Frequently, but not always, syndecan-1 levels decrease as tumor grade, stage and invasiveness and dedifferentiation increase. This parallels experiments that show depletion of syndecan-1 can be accompanied by loss of cadherin-mediated adhesion. However, in some tumors, levels of syndecan-1 increase, but the characterization of its distribution is relevant. There can be loss of membrane staining, but acquisition of cytoplasmic and/or nuclear staining that is abnormal. Moreover, the appearance of syndecan-1 in the tumor stroma, either associated with its cellular component or the collagenous matrix, is nearly always a sign of poor prognosis. Given its relevance to myeloma progression, syndecan-1-directed antibody—toxin conjugates are being tested in clinical and preclinical trials, and may have future relevance to some carcinomas. |
format | Online Article Text |
id | pubmed-8072910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80729102021-04-27 Syndecan-1 (CD138), Carcinomas and EMT Couchman, John R. Int J Mol Sci Review Cell surface proteoglycans are known to be important regulators of many aspects of cell behavior. The principal family of transmembrane proteoglycans is the syndecans, of which there are four in mammals. Syndecan-1 is mostly restricted to epithelia, and bears heparan sulfate chains that are capable of interacting with a large array of polypeptides, including extracellular matrix components and potent mediators of proliferation, adhesion and migration. For this reason, it has been studied extensively with respect to carcinomas and tumor progression. Frequently, but not always, syndecan-1 levels decrease as tumor grade, stage and invasiveness and dedifferentiation increase. This parallels experiments that show depletion of syndecan-1 can be accompanied by loss of cadherin-mediated adhesion. However, in some tumors, levels of syndecan-1 increase, but the characterization of its distribution is relevant. There can be loss of membrane staining, but acquisition of cytoplasmic and/or nuclear staining that is abnormal. Moreover, the appearance of syndecan-1 in the tumor stroma, either associated with its cellular component or the collagenous matrix, is nearly always a sign of poor prognosis. Given its relevance to myeloma progression, syndecan-1-directed antibody—toxin conjugates are being tested in clinical and preclinical trials, and may have future relevance to some carcinomas. MDPI 2021-04-19 /pmc/articles/PMC8072910/ /pubmed/33921767 http://dx.doi.org/10.3390/ijms22084227 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Couchman, John R. Syndecan-1 (CD138), Carcinomas and EMT |
title | Syndecan-1 (CD138), Carcinomas and EMT |
title_full | Syndecan-1 (CD138), Carcinomas and EMT |
title_fullStr | Syndecan-1 (CD138), Carcinomas and EMT |
title_full_unstemmed | Syndecan-1 (CD138), Carcinomas and EMT |
title_short | Syndecan-1 (CD138), Carcinomas and EMT |
title_sort | syndecan-1 (cd138), carcinomas and emt |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072910/ https://www.ncbi.nlm.nih.gov/pubmed/33921767 http://dx.doi.org/10.3390/ijms22084227 |
work_keys_str_mv | AT couchmanjohnr syndecan1cd138carcinomasandemt |